#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Infertility male Propionic acidaemia Diffuse large B-cell lymphoma Lennox-Gastaut syndrome Netherton's syndrome Craniopharyngioma Retinal artery occlusion Infection in an immunocompromised host Mixed-type liposarcoma Myelodysplastic syndrome with excess blasts Heavy menstrual bleeding Pyruvate dehydrogenase complex deficiency Piriformis syndrome Squamous cell carcinoma of the cervix Myelodysplastic syndrome More trials…

    Learn about Rare Diseases

    Gaucher’s disease type I Rhabdomyosarcoma recurrent – Diagnostics Paroxysmal nocturnal haemoglobinuria – Diagnostics Ocular melanoma – Diagnostics Haemophilia B without inhibitors – Basic Information Retinitis pigmentosa – Trials in Disease MELAS syndrome – Treatment Leukoencephalopathy – Diagnostics Myelodysplastic syndrome with excess blasts – Diagnostics Cerebral arteriovenous malformation haemorrhagic – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Voriconazole Cinchocaine Hydrochloride Suxamethonium Chloride IMEROPRUBART Ivosidenib Vgl101 Fosinopril Sodium Ascorbic Acid Midostaurin Mitazalimab Mps-200 Plerixafor Stro-002 Epirubicin Panitumumab Asciminib Hydrochloride Citalopram Hydrochloride Human Von Willebrand Factor Astegolimab Paclitaxel Obaluronate More therapies…

    Learn about Your Condition

    Eye inflammation Immune-mediated enterocolitis Post procedural complication Retinopathy of prematurity Sleep disorder Coronary artery bypass Osteosarcoma Oesophageal adenocarcinoma Hypervolaemia Acarodermatitis Lichen planopilaris Leber's congenital amaurosis Malignant melanoma stage IV Thalassaemia alpha Relapsing multiple sclerosis More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Skin and Connective Tissue Diseases

  • Study on the Effectiveness of Pembrolizumab and Lenvatinib for Patients with Resectable Mucosal Melanoma

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Malignant melanoma
    Investigated Drugs:
    • Lenvatinib
    • Pembrolizumab
    France

  • Study on Tildrakizumab for Patients with Active Psoriatic Arthritis Who Have Not Used Anti-TNF Therapy

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Psoriatic arthropathy
    Investigated Drugs:
    • Tildrakizumab
    Czechia Germany Poland Spain

  • Study on Amlitelimab for Patients Aged 12 and Older with Moderate-to-Severe Atopic Dermatitis

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Amlitelimab
    • Pimecrolimus
    • Tacrolimus
    Bulgaria Czechia Denmark France Germany Greece +5

  • Study Comparing Risankizumab and Deucravacitinib for Adults with Moderate Plaque Psoriasis Eligible for Systemic Therapy

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Psoriasis
    Investigated Drugs:
    • Risankizumab
    • Deucravacitinib
    Belgium Germany Greece Hungary Italy The Netherlands +1

  • Study on the Safety of Tirbanibulin and Diclofenac Sodium for Adults with Actinic Keratosis on the Face or Scalp

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Tirbanibulin
    • Diclofenac Sodium
    France Germany Italy Poland Spain

  • Study on the Effectiveness and Safety of Ruxolitinib Cream for Adults with Chronic Hand Eczema

    Not recruiting

    2 1
    Investigated Diseases:
    • Hand dermatitis
    Investigated Drugs:
    • Ruxolitinib
    Germany Poland
Previous Page
1 … 51 52 53 54 55 … 66
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!